Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma

Official record

Identifier

NCT07573215

Recruiting locations

countries

United StatesPuerto Rico

Interventions studied

daraxonrasib

Lead sponsor

Revolution Medicines, Inc.

Target enrolment

Not provided in the official record

Study type

EXPANDED_ACCESS

Phase

Not provided in the official record

Status

available

First posted

May 7, 2026

Last updated on the registry

Jul 31, 2026

Age

18 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* At least 18 years old and has provided informed consent.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Histologically or cytologically confirmed PDAC with metastatic disease.
* Evidence of active disease progression during or following the most recent line of systemic therapy for PDAC, based on investigator assessment.
* At least one prior line of systemic therapy in the metastatic setting, which must include either a fluoropyrimidine-based or gemcitabine-based regimen.
* Received and progressed, been intolerant to prior standard therapy, or no longer expected to benefit from standard therapies.
* Adequate bone marrow, renal, hepatic, and coagulation functions.
* Ineligible for, or unable to enroll in, another clinical trial of daraxonrasib, if available.
* Able to take oral medications

Exclusion Criteria:

* History of known central nervous system metastatic disease.
* Concurrent systemic anticancer therapy.
* Significant cardiovascular disease.
* Major GI conditions that may affect the ability to take or absorb daraxonrasib (patients with prior Whipple procedure are eligible).
* Active uncontrolled systemic infection.
* Major surgery within 28 days before enrollment.
* Additional inclusion and exclusion criteria may apply.

Indexed under

Pancreatic Cancer